| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2000;36:581.)
© 2000 American Heart Association, Inc.
Scientific Contributions |
From the Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Correspondence to Koji Fujii, MD, PhD, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka, 812-8582, Japan. E-mail fujii{at}intmed2.med.kyushu-u.ac.jp
| Abstract |
|---|
|
|
|---|
Key Words: endothelium-derived factor arteries aging drugs renin-angiotensin system
| Introduction |
|---|
|
|
|---|
ACE inhibitors are presently used not only in patients with hypertension but also in patients with other cardiovascular diseases, such as chronic heart failure and/or myocardial infarction. In the Trial on Reversing Endothelial Dysfunction (TREND) study,17 which was a randomized study conducted in normotensive patients with coronary artery disease, chronic treatment with the ACE inhibitor quinapril improved the epicardial arterial response to ACh. Therefore, it is conceivable that ACE inhibitors may have a favorable influence on endothelial function even in normotensive subjects.
On the basis of these experimental and clinical findings, we hypothesized that chronic treatment with ACE inhibitors may improve EDHF-mediated hyperpolarization and relaxation in normotensive rats. Because EDHF-mediated hyperpolarization declines with aging,12 special attention was given to clarify a possible treatment effect on age-related changes in the response. For this purpose, we treated WKY with either enalapril (WKY-E) or a combination of hydralazine and hydrochlorothiazide (WKY-H) from 9 to 12 months of age. Age-matched 12-month-old WKY (WKY-O) and 3-month-old WKY (WKY-Y) both served as controls.
| Methods |
|---|
|
|
|---|
Systolic blood pressure was measured in conscious rats before and at the end of the treatment period. The drugs were withdrawn 2 days before the experiments. The rats were anesthetized with ether and killed by decapitation. The main branch of the mesenteric artery was excised and bathed in cold Krebs solution of the following composition (mmol/L): Na+ 137.4, K+ 5.9, Mg2+ 1.2, Ca2+ 2.5, HCO3- 15.5, H2PO4- 1.2, Cl- 134, and glucose 11.5. The artery was cut into rings of 3 and 1.2 mm for the electrophysiological and tension experiments, respectively.
Electrophysiological Experiments
Transverse strips cut along the longitudinal axis of the rings
were placed in the experimental chamber with the
endothelial layer up. Tissues were carefully pinned to
the rubber base attached to the bottom of the 2-mL chamber and then
superfused with 36°C Krebs solution aerated with 95%
O2/5% CO2 (pH 7.3 to 7.4)
at a rate of 3 mL/min. After equilibration for at least 60 minutes, the
membrane potentials of vascular smooth muscle cells were recorded,
as described previously.7 12 16
Briefly, conventional glass capillary microelectrodes filled with 3
mol/L KCl and with tip resistances of 50 to 80 M
were inserted into
the smooth muscle cells from the endothelial side.
Criteria for successful insertion included the following: an abrupt
drop in voltage when the microelectrode was impaled into the vascular
smooth muscle cell, a stable membrane potential for at least 2 minutes,
and a sharp return to zero potential on withdrawal of the electrode.
Electrical signals were amplified through an amplifier (MEZ-7200, Nihon
Koden), monitored on an oscilloscope (VC-11, Nihon Koden), and
recorded with a pen recorder (RJG-4002, Nihon Koden).
ACh (Sigma) was applied either during the resting state of the membrane or under depolarization with 10-5 mol/L norepinephrine (NE, Sigma). Each dose of ACh was applied separately after an appropriate washout period. Levcromakalim (a gift from SmithKline Beecham Pharmaceuticals, Worthing, UK), a direct activator of ATP-sensitive K+ channels,10 was applied in a cumulative manner.
Isometric Tension Recording
Rings with intact endothelium were placed in the
5-mL organ chambers filled with 36°C Krebs solution aerated with
93% O2/7% CO2 (pH 7.4).
Two fine stainless-steel wires were placed through the lumen of the
ring; one was anchored, and the other was attached to the
mechanotransducer (UM-203, Kishimoto). After the rings were allowed to
equilibrate for 60 minutes at an optimal resting tension of 1.0
g,7 12 they were challenged with 40 mmol/L KCl until
the contractions became steady.
Subsequently, the rings were allocated to one of the following in vitro treatments: (1) control, (2) 10-5 mol/L indomethacin (Sigma), (3) indomethacin and 10-4 mol/L NG-nitro-L-arginine (L-NNA, Sigma), and (4) indomethacin, L-NNA, and 20 mmol/L KCl. Indomethacin is an inhibitor of cyclooxygenase, and L-NNA is an inhibitor of NO synthase. The rings were contracted with 10-5 mol/L NE. After the contractions had reached a steady level, the relaxant effects of ACh were studied by adding the drug in increasing concentrations, from 10-9 to 10-5 mol/L.
In some preparations, the rings were contracted with 77 mmol/L KCl solution in the presence of 10-5 mol/L indomethacin, and a relaxation response to ACh was observed. Relaxation in response to levcromakalim and sodium nitroprusside (Sigma) was studied in rings contracted with 10-5 mol/L NE in the presence of 10-5 mol/L indomethacin. The extent of the relaxation was expressed as the percentage of the initial contraction evoked by the contractile agonist.
Acute Effects of Angiotensin II
In some mesenteric arteries from WKY-Y, direct effects of
angiotensin II (Sigma) on ACh-induced
hyperpolarization and relaxation were examined
under in vitro conditions. Relaxations to ACh in the presence or
absence of 10-7 mol/L
angiotensin II were examined in rings precontracted with
10-5 mol/L NE in the
presence of indomethacin
(10-5 mol/L) and L-NNA
(10-4 mol/L).
Drugs and Solutions
The solutions containing 20 or 77 mmol/L KCl were obtained
by equimolar replacement of NaCl by KCl in Krebs solution.
Indomethacin was dissolved in 10 mmol/L
Na2CO3; L-NNA, in 0.2 mol/L
HCl; and levcromakalim, in 90% ethanol. All drugs were further diluted
1000 times in Krebs solution to produce the final bath
concentrations.
Statistical Analysis
Results are given as mean±SEM. The concentration-response
curves of hyperpolarization and relaxation were
analyzed by 2-way ANOVA followed by the Scheffé test for
multiple comparisons. The concentrations of agonists causing
half-maximal responses (EC50 value) were also
calculated for hyperpolarizations and relaxations
by nonlinear regression analysis. The
EC50 values were expressed as the negative
logarithm of the molar concentration (pD2
values). Other variables were analyzed by 1-way ANOVA
followed by the Scheffé test for multiple comparisons or paired
Student t test. A level of P<0.05 was considered
statistically significant.
| Results |
|---|
|
|
|---|
|
Resting Membrane Potential in Mesenteric Arteries
The resting membrane potential of smooth muscle cells of the
mesenteric artery did not differ among the study groups (WKY-O,
-49.6±0.5 mV; WKY-E, -50.3±1.3 mV; WKY-H, -50.3±2.2 mV; and
WKY-Y, -48.8±1.2 mV [P=NS for all]).
Endothelium-Dependent
Hyperpolarization in Mesenteric Arteries
Dose-response curves of the hyperpolarization
in response to ACh, applied in the resting state of the membrane, are
shown in Figure 1. ACh-induced
hyperpolarization was significantly smaller in
WKY-O than in WKY-Y (P<0.05). Enalapril treatment (WKY-E)
but not the combination of hydralazine and
hydrochlorothiazide (WKY-H) led to a significant
improvement in hyperpolarization compared with the
control condition (WKY-O) (P<0.05), and the response
attained in WKY-E was comparable to that in WKY-Y
(pD2 values: WKY-O, 7.1±0.1; WKY-E, 7.2±0.1;
WKY-H, 7.1±0.1; and WKY-Y, 7.0±0.1 [P=NS for all];
maximal hyperpolarization: WKY-O, -10.2±1.3 mV
[P<0.05 versus WKY-Y]; WKY-E, -15.9±1.4 mV
[P<0.05 versus WKY-O]; WKY-H, -10.3±1.0 mV
[P<0.05 versus WKY-Y]; and WKY-Y, -17.3±1.4 mV
[P<0.05 versus WKY-O]).
|
Representative tracings and a summary of the data of ACh-induced hyperpolarization under conditions of depolarization with 10-5 mol/L NE in the presence of 10-5 mol/L indomethacin are shown in Figure 2. Vessels were preincubated with 10-5 mol/L indomethacin to eliminate the possible depolarizing actions of cyclooxygenase products known to be released under these conditions.14 15 16 The degree of depolarization produced by 10-5 mol/L NE, as measured at the bottom of the oscillatory response, was comparable among the 4 study groups (data not shown). ACh-induced hyperpolarization was generally greater in the presence of NE than in the absence of NE. Because EDHF-mediated hyperpolarization is thought to be mainly due to an opening of K+ channels, less negative membrane potential in the presence of NE may allow the membrane to hyperpolarize to a greater extent toward K+ equilibrium potential. ACh-induced hyperpolarization in the presence of NE was attenuated in WKY-O compared with WKY-Y. Enalapril treatment (WKY-E) but not the combination therapy (WKY-H) improved ACh-induced hyperpolarizations compared with the control condition (WKY-O), and no significant difference was observed between the responses in WKY-E and WKY-Y.
|
Endothelium-Dependent Relaxation in Mesenteric
Arteries
In mesenteric arterial rings precontracted with
10-5 mol/L NE in the
absence of indomethacin
(10-5 mol/L), ACh produced
a dose-dependent relaxation in all groups (Figure 3A, Table 2). The maximal relaxation was
significantly smaller in WKY-O than in WKY-Y. Pretreatment with
indomethacin augmented the relaxation in arteries from
12-month-old WKY groups, especially in WKY-O arteries (Figure 3A and 3B). In the presence of indomethacin, relaxations
to ACh did not differ significantly among the 4 study groups, although
the responses tended to be greater in WKY-Y.
|
|
The NO synthase inhibitor L-NNA (10-4 mol/L) significantly inhibited relaxations to ACh, but substantial relaxation remained after exposure to both indomethacin and L-NNA in all groups (Figure 3C, Table 2). This residual relaxation was abolished by a high-KCl solution (20 mmol/L). The L-NNAresistant relaxation to ACh was significantly smaller in WKY-O than in WKY-Y. Enalapril treatment (WKY-E) but not the combination of hydralazine and hydrochlorothiazide (WKY-H) significantly improved the L-NNAresistant relaxation to ACh to a level comparable to that in WKY-Y (Figure 3C, Table 2).
When rings pretreated with indomethacin were contracted with 77 mmol/L KCl to eliminate EDHF-mediated hyperpolarization,16 18 no difference was found in the relaxation produced in response to ACh among the 4 groups (pD2 values: WKY-O, 6.4±0.1; WKY-E, 6.1±0.2; WKY-H, 6.2±0.1; and WKY-Y, 6.5±0.1 [P=NS for all]; maximal relaxation: WKY-O, 63.0±3.2%; WKY-E, 52.3±8.1%; WKY-H, 56.6±2.2%; and WKY-Y, 63.9±1.1% [P=NS for all]). This relaxation was abolished by further incubation with 10-4 mol/L L-NNA (data not shown).
Endothelium-Independent
Hyperpolarization and Relaxation
Levcromakalim produced a comparable degree of
hyperpolarization in the mesenteric arteries in all
groups (pD2 values: WKY-O, 6.8±0.1; WKY-E,
6.8±0.1; WKY-H, 6.8±0.1; and WKY-Y, 7.0±0.1 [P=NS for
all]; maximal hyperpolarization: WKY-O,
-26.1±1.1 mV; WKY-E, -25.4.±1.7 mV; WKY-H, -26.2±1.0 mV; and
WKY-Y, -23.6±0.2 mV [P=NS for all]). The
levcromakalim-induced relaxation in rings precontracted with
10-5 mol/L NE was also
similar among the 4 groups (Table 2).
The maximum relaxations to sodium nitroprusside, an NO donor, in rings precontracted with 10-5 mol/L NE did not differ among the 12-month-old WKY groups (Table 2), but the response was significantly smaller in WKY-O than in WKY-Y.
Effects of Enalapril Treatment on EDHF-Mediated
Hyperpolarization and Relaxation in Young
WKY
One-month treatment of 8-week-old WKY (WKY-Y-E) lowered
systolic blood pressure from 148.0±3.4 to 123.0±5.0
mm Hg (n=4, P<0.05 for before versus after treatment).
ACh-induced hyperpolarizations in mesenteric
arteries in the absence or presence of NE in WKY-Y-E were not different
from those in WKY-Y (pD2 values in the absence of
NE: WKY-Y, 7.0±0.1; WKY-Y-E, 6.7±0.1 [P=NS]; maximal
hyperpolarization in the absence of NE: WKY-Y,
-17.3±1.4 mV; WKY-Y-E, -16.8±2.8 mV [P=NS];
hyperpolarization to
10-7 mol/L ACh in the
presence of 10-5 mol/L NE:
WKY-Y, -15.7±2.3 mV; WKY-Y-E, -9.5±1.7 mV [P=NS];
hyperpolarization to
10-5 mol/L ACh in the
presence of 10-5 mol/L NE:
WKY-Y, -28.3±0.4 mV; WKY-Y-E, -25.0±2.6 mV [P=NS]).
ACh-induced relaxation in rings precontracted with
10-5 mol/L NE in the
presence of indomethacin and L-NNA also did not differ
in WKY-Y and WKY-Y-E (pD2 values: WKY-Y,
6.3±0.1; WKY-Y-E, 6.6±0.2 [P=NS]; maximal relaxation:
WKY-Y, 72.2±3.9%; WKY-Y-E, 75.1±4.9% [P=NS]).
Acute Effects of Angiotensin II on EDHF-Mediated
Hyperpolarization and Relaxation
Angiotensin II
(10-7 mol/L) depolarized
the membrane from -54±0.7 to -45±1.4 mV (n=4, P<0.05).
ACh (10-6 mol/L)induced
hyperpolarization was -12.0±1.2 and -13.4±1.5
mV before and after application of angiotensin II
(10-7 mol/L), respectively
(n=4, P=NS). ACh-induced relaxation in rings precontracted
with 10-5 mol/L NE in the
presence of indomethacin and L-NNA was similar in the
absence and presence of
10-7mol/L
angiotensin II (pD2 values: 6.6±0.1
and 6.8±0.1, respectively [n=4, P=NS]; maximal
relaxation: 69.9±9.9% and 72.8±9.9%, respectively [n=4,
P=NS]).
| Discussion |
|---|
|
|
|---|
In the rat mesenteric artery, ACh-induced
hyperpolarization is mediated by EDHF, but not by
NO or prostacyclins.7 19 20 On the other hand, ACh-induced
relaxation in this preparation is determined by the balance of NO,
EDHF, and endothelium-derived contracting
factor,7 14 15 and the EDHF-mediated relaxation can be
assessed by the relaxation under the combined blockade of
cyclooxygenase and NO
synthase.7 16 18 19 20 This is the first study to
demonstrate that chronic treatment with the ACE inhibitor
improves EDHF-mediated hyperpolarization and
relaxation in normotensive rats. In our previous study, EDHF-mediated
responses in mesenteric arteries were attenuated in aged WKY (aged
24
months) compared with younger WKY.12 In the present
study, EDHF-mediated hyperpolarization and
relaxation were significantly smaller in untreated 12-month-old WKY
than in 3-month-old WKY, suggesting that the age-related decline in the
EDHF-mediated responses may already be evident at the age of
12
months in rats.21 The fact that chronic enalapril
treatment eliminated the difference in the EDHF-mediated responses
between young and older WKY suggests that the ACE inhibitor
prevents the age-related deterioration in the EDHF responses.
In the present study, enalapril, but not a combination of hydralazine and hydrochlorothiazide, improved EDHF-mediated hyperpolarization and relaxation, despite a comparable reduction in blood pressure. These results suggest that inhibition of the renin-angiotensin system plays a major role in improving EDHF-mediated responses in normotensive rats and that blood pressure reduction alone is not sufficient for this effect. However, we cannot totally rule out the possibility that both renin-angiotensin system blockade and blood pressure lowering are required for the observed benefit.
The underlying mechanisms of the improvement in EDHF-mediated responses by ACE inhibitors remain unclear from the present findings alone. The improvement cannot be explained by the general improvement in the smooth muscle sensitivity to hyperpolarizing or vasodilatory stimuli, because hyperpolarization and relaxation to levcromakalim, a direct activator of ATP-sensitive K+ channels,10 and relaxation to nitroprusside, an NO donor, were not different for treated and untreated 12-month-old WKY. ACE inhibitors augment bradykinin-induced EDHF-mediated hyperpolarization in canine and human arteries, presumably through an inhibition of bradykinin breakdown.22 23 However, such an effect of ACE inhibitors is unlikely to explain the present findings in the rat, because the drugs were withdrawn before the experiments and because, in our previous study, in vitro incubation with ACE inhibitors did not affect ACh-induced hyperpolarization in the rat arteries.16 Furthermore, in the present study, angiotensin II did not appear to directly affect EDHF-mediated hyperpolarization and relaxation. Aging is associated with structural changes in the vascular wall, such as subendothelial thickening, and it is conceivable that such structural changes limit the diffusion of EDHF. It remains to be clarified whether the age-related decline in endothelial function and its improvement in response to ACE inhibitors are associated with vascular structural changes.
ACh-induced relaxations in rings contracted with NE in the presence of indomethacin but in the absence of NO synthase inhibitors may be accounted for by both NO and EDHF.7 18 In the present study, ACh-induced relaxation under this condition was not different among the study groups. Furthermore, the NO-mediated relaxation, which can be assessed by relaxation to ACh in rings precontracted with high KCl,16 18 was also comparable among the 4 groups, suggesting that the NO system in this particular preparation is preserved at least up to the age of the rats studied and is not modulated by drug therapy. It has been suggested that EDHF may serve as a backup system for NO.24 Even in WKY-O, ACh still evoked a certain amount of hyperpolarization, and we speculate that preserved NO-induced relaxation together with some hyperpolarization in WKY-O may manage to maintain a comparable relaxation to ACh under the above condition.
Several previous studies have examined the chronic effects of ACE inhibitors on endothelial function in normotensive rats. In a study by Kähönen et al,25 in which WKY were treated with quinapril from 7 to 17 weeks of age, no difference was found in the relaxation response to ACh in mesenteric arteries between treated and untreated rats in the presence or absence of NO synthase inhibitors. The difference in the results between their study and the present study might arise from the difference in the age of the rats; ie, in their study, even after the treatment period, the rats were only 17 weeks old, an age at which EDHF-mediated responses may well be preserved.12 21 This notion is also supported by the present observation that 1 month of treatment of young WKY with enalapril did not affect EDHF-mediated hyperpolarization and relaxation.
On the other hand, a 6-week treatment of Wistar rats with either enalapril26 or ramipril27 has been shown to improve endothelium-dependent relaxation in the aorta. However, EDHF-mediated relaxation was not assessed in these studies, and moreover, contribution of EDHF to relaxation is of minor importance in the rat aorta.28 Indeed, ramipril might improve the relaxation by enhancing NO availability after bradykinin accumulation.27 Atkinson et al29 have examined the effects of long-term treatment (from 6 up to 30 months of age) with the ACE inhibitor perindopril on vasodilator responses in the perfused mesenteric vascular bed of normotensive rats. They found that such treatment prevents the decline in dilator response to carbachol; however, this decline is evident only in very old rats (30 months of age). Again, no information is available regarding the relative contribution of EDHF to the relaxation. Therefore, the present study is clearly distinct from previous studies in that the ACE inhibitor improves EDHF-mediated responses presumably by alleviating early endothelial dysfunction associated with aging process. The EDHF system functions in human arteries22 30 and may also decline with aging.30 It remains to be clarified whether the clinical benefits of ACE inhibitors are associated with any changes in the EDHF system. It also remains to be determined whether angiotensin II type 1 receptor antagonists or their combination with ACE inhibitors exerts effects similar to those of ACE inhibitors.
In conclusion, the present study has demonstrated that the treatment of normotensive rats with ACE inhibitors prevents the age-related decline in endothelium-dependent hyperpolarization and relaxation via EDHF, primarily through their specific actions on the renin-angiotensin system. The possibility that the early functional aging process of the vascular endothelium could be modulated by drugs that inhibit the renin-angiotensin system may warrant further investigation.
| Acknowledgments |
|---|
Received November 30, 1999; first decision January 3, 2000; accepted April 18, 2000.
| References |
|---|
|
|
|---|
2. Feletou M, Vanhoutte PM. Endothelium-dependent hyperpolarization of canine coronary smooth muscle. Br J Pharmacol. 1988;93:515524.[Medline] [Order article via Infotrieve]
3. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:11651174.[Medline] [Order article via Infotrieve]
4.
Cohen RA, Vanhoutte PM.
Endothelium-dependent
hyperpolarization: beyond nitric oxide and cyclic
GMP. Circulation. 1995;92:33373349.
5.
Chen G, Suzuki H. Some electrical properties of the
endothelium-dependent
hyperpolarization recorded from rat
arterial smooth muscle cells. J Physiol
(Lond). 1989;410:91106.
6.
Kauser K, Stekiel WJ, Rubanyi G, Harder DR. Mechanism
of action of EDRF on pressurized arteries: effect on
K+ conductance. Circ Res. 1989;65:199204.
7.
Fujii K, Tominaga M, Ohmori S, Kobayashi K, Koga T,
Takata Y, Fujishima M. Decreased endothelium-dependent
hyperpolarization to acetylcholine in smooth muscle
of the mesenteric artery of spontaneously hypertensive rats. Circ
Res. 1992;70:660669.
8.
Campbell WB, Gebremedhin D, Pratt PF, Harder DR.
Identification of epoxyeicosatrienoic acids as
endothelium-derived hyperpolarizing factors. Circ
Res. 1996;78:415423.
9. Fisslthaler B, Popp R, Kiss L, Potente M, Harder DR, Fleming I, Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature. 1999;401:493497.[Medline] [Order article via Infotrieve]
10. Edwards G, Dora KA, Gardener MJ, Garland CJ, Weston AH. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269272.[Medline] [Order article via Infotrieve]
11.
Yamamoto Y, Imaeda K, Suzuki H.
Endothelium-dependent
hyperpolarization and intracellular electrical
coupling in guinea-pig mesenteric arterioles. J Physiol
(Lond). 1999;514:505513.
12.
Fujii K, Ohmori S, Tominaga M, Abe I, Takata Y, Ohya Y,
Kobayashi K, Fujishima M. Age-related changes in
endothelium-dependent
hyperpolarization in the rat mesenteric artery.
Am J Physiol. 1993;265:H509H516.
13.
Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A,
Fasolo CB, Sudano I, Salvetti A. Aging and endothelial
function in normotensive subjects and patients with essential
hypertension. Circulation. 1995;91:19811987.
14.
Vanhoutte PM. Endothelium and control
of vascular function: state of the art lecture.
Hypertension. 1989;13:658667.
15.
Lüscher TF, Boulanger CM, Dohi Y, Yang ZH.
Endothelium-derived contracting factors.
Hypertension. 1992;19:117130.
16.
Onaka U, Fujii K, Abe I, Fujishima M. Antihypertensive
treatment improves endothelium-dependent
hyperpolarization in the mesenteric artery of
spontaneously hypertensive rats. Circulation. 1998;98:175182.
17.
Mancini GB, Henry GC, Macaya C, ONeill BJ, Pucillo
AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, et
al. Angiotensin-converting enzyme inhibition with quinapril
improves endothelial vasomotor dysfunction in patients
with coronary artery disease: the TREND (Trial on Reversing
ENdothelial Dysfunction) study. Circulation.. 1996;94:258265.
18. Adeagbo AS, Triggle CR. Varying extracellular [K+]: a functional approach to separating EDHF- and EDNO-related mechanisms in perfused rat mesenteric arterial bed. J Cardiovasc Pharmacol. 1993;21:423429.[Medline] [Order article via Infotrieve]
19. Garland CJ, McPherson GA. Evidence that nitric oxide does not mediate the hyperpolarization and relaxation to acetylcholine in the rat small mesenteric artery. Br J Pharmacol. 1992;105:429435.[Medline] [Order article via Infotrieve]
20.
Chen G, Cheung DW. Modulation of
endothelium-dependent
hyperpolarization and relaxation to acetylcholine
in rat mesenteric artery by cytochrome P450 enzyme activity. Circ
Res. 1996;79:827833.
21. Nakashima M, Vanhoutte PM. Decreased endothelium-dependent hyperpolarization with aging and hypertension in the rat mesenteric artery. In: Vanhoutte PM, ed. Endothelium-Derived Hyperpolarizing Factor. Amsterdam, the Netherlands: Harwood Academic Publishers; 1996:227233.
22. Nakashima M, Mombouli JV, Taylor AA, Vanhoutte PM. Endothelium-dependent hyperpolarization caused by bradykinin in human coronary arteries. J Clin Invest. 1993;92:28672871.
23.
Mombouli J-V, Illiano S, Nagao T, Scott-Burden T,
Vanhoutte PM. Potentiation of endothelium-dependent
relaxations to bradykinin by angiotensin I converting
enzyme inhibitors in canine coronary artery
involves both endothelium-derived relaxing and
hyperpolarizing factors. Circ Res. 1992;71:137144.
24.
Bauersachs J, Rüdiger P, Hecker M, Sauer E,
Fleming I, Busse R. Nitric oxide attenuates the release of
endothelium-derived hyperpolarizing factor.
Circulation. 1996;94:33413347.
25. Kähönen M, Mäkynen H, Wu X, Arvola P, Pörsti I. Endothelial function in spontaneously hypertensive rats: influence of quinapril treatment. Br J Pharmacol. 1995;115:859867.[Medline] [Order article via Infotrieve]
26. Bossaller C, Auch-Schwelk W, Weber F, Götze S, Gräfe M, Graf K, Fleck E. Endothelium-dependent relaxations are augmented in rats chronically treated with the angiotensin-converting enzyme inhibitor enalapril. J Cardiovasc Pharmacol. 1992;20(suppl 9):S91S95.
27.
Berkenboom G, Brékine D, Unger P, Grosfils K,
Staroukine M, Fontaine J. Chronic
angiotensin-converting enzyme inhibition and
endothelial function of rat aorta.
Hypertension. 1995;26:738743.
28. Shimokawa H, Yasutake H, Fujii K, Owada MK, Nakaike R, Fukumoto Y, Takayanagi T, Nagao T, Egashira K, Fujishima M, et al. The importance of the hyperpolarizing mechanism increases as the vessel size decreases in endothelium-dependent relaxations in rat mesenteric circulation. J Cardiovasc Pharmacol. 1996;28:703711.[Medline] [Order article via Infotrieve]
29.
Atkinson J, Tatchum-Talom R, Corman B. Effects of
chronic ANG I-converting enzyme inhibition on aging processes, III:
endothelial function of mesenteric arterial
bed of rats. Am J Physiol. 1994;267:R136R143.
30. Urakami-Harasawa L, Shimokawa H, Nakashima M, Egashira K, Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997;100:27932799.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
H. Bulckaen, G. Prevost, E. Boulanger, G. Robitaille, V. Roquet, C. Gaxatte, G. Garcon, B. Corman, P. Gosset, P. Shirali, et al. Low-dose aspirin prevents age-related endothelial dysfunction in a mouse model of physiological aging Am J Physiol Heart Circ Physiol, April 1, 2008; 294(4): H1562 - H1570. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Piotrkowski, C. G. Fraga, and E. M. V. de Cavanagh Mitochondrial function and nitric oxide metabolism are modified by enalapril treatment in rat kidney Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2007; 292(4): R1494 - R1501. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Toda, K. Ayajiki, and T. Okamura Interaction of Endothelial Nitric Oxide and Angiotensin in the Circulation Pharmacol. Rev., March 1, 2007; 59(1): 54 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Barton Ageing as a determinant of renal and vascular disease: role of endothelial factors Nephrol. Dial. Transplant., March 1, 2005; 20(3): 485 - 490. [Full Text] [PDF] |
||||
![]() |
Y. Kansui, K. Fujii, K. Nakamura, K. Goto, H. Oniki, I. Abe, Y. Shibata, and M. Iida Angiotensin II receptor blockade corrects altered expression of gap junctions in vascular endothelial cells from hypertensive rats Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H216 - H224. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Cipollone, E. Toniato, S. Martinotti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, S. Ursi, G. Vitullo, M. Averna, et al. A Polymorphism in the Cyclooxygenase 2 Gene as an Inherited Protective Factor Against Myocardial Infarction and Stroke JAMA, May 12, 2004; 291(18): 2221 - 2228. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Sandow, K. Goto, N. M. Rummery, and C. E. Hill Developmental changes in myoendothelial gap junction mediated vasodilator activity in the rat saphenous artery J. Physiol., May 1, 2004; 556(3): 875 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Woodman, E. M. Price, and M. H. Laughlin Selected Contribution: Aging impairs nitric oxide and prostacyclin mediation of endothelium-dependent dilation in soleus feed arteries J Appl Physiol, November 1, 2003; 95(5): 2164 - 2170. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Wang, G. Takagi, K. Asai, R. G. Resuello, F. F. Natividad, D. E. Vatner, S. F. Vatner, and E. G. Lakatta Aging Increases Aortic MMP-2 Activity and Angiotensin II in Nonhuman Primates Hypertension, June 1, 2003; 41(6): 1308 - 1316. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Ulker, P. P. McKeown, and U. Bayraktutan Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities Hypertension, March 1, 2003; 41(3): 534 - 539. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Thomsen, I. Rubin, and M. Lauritzen NO- and non-NO-, non-prostanoid-dependent vasodilatation in rat sciatic nerve during maturation and developing experimental diabetic neuropathy J. Physiol., September 15, 2002; 543(3): 977 - 993. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Mukai, H. Shimokawa, M. Higashi, K. Morikawa, T. Matoba, J. Hiroki, I. Kunihiro, H. M.A. Talukder, and A. Takeshita Inhibition of Renin-Angiotensin System Ameliorates Endothelial Dysfunction Associated With Aging in Rats Arterioscler Thromb Vasc Biol, September 1, 2002; 22(9): 1445 - 1450. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Armstrong, Y. Zhang, K. G. Stewart, and S. T. Davidge Estrogen replacement reduces PGHS-2-dependent vasoconstriction in the aged rat Am J Physiol Heart Circ Physiol, September 1, 2002; 283(3): H893 - H898. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.M. Vanhoutte Ageing and endothelial dysfunction Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A8 - A17. [Abstract] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |